BioGenCell raises $16m. for chronic disease treatment
The company’s treatment has already prevented loss of limb in several patients during Phase I trials.
Microglia (green) that were “matured” in the lab from stem cells of ALS patients; the cells’ nuclei are in blue. Viewed with confocal microscopy(photo credit: WEIZMANN INSTITUTE OF SCIENCE)Updated: 
